Univariate and multivariate prognostic analysis
| . | NOTCH1 . | NOTCH1/FBXW7 . | ||||
|---|---|---|---|---|---|---|
| Univariate P (95% CI) . | Multivariate HR (95% CI) . | P . | Multivariate HR (95% CI) . | P . | ||
| For EFS | ||||||
| In all patients | ||||||
| Age* | .22 | NA | NA | NA | NA | |
| WBC† | .08 | 1.11 (0.92-1.34) | .29 | 1.10 (0.91-1.32) | .33 | |
| GRAALL-2003 trial | < .001 | 0.44 (0.26-0.75) | .002 | 0.43 (0.25-0.72) | .001 | |
| NOTCH mutation | .03 | 0.68 (0.44-1.06) | .9 | NA | NA | |
| NOTCH1/FBXW7 mutation | .01 | NA | NA | 0.58 (0.37-0.92) | .02 | |
| In the 127 pateints tested for TLX1 expression | ||||||
| Age* | .27 | NA | NA | NA | NA | |
| WBC† | .05 | 1.12 (0.92-1.36) | .28 | 1.11 (0.92-1.35) | .28 | |
| GRAALL-2003 trial | < .001 | 0.42 (0.24-0.73) | .002 | 0.39 (0.22-0.69) | .001 | |
| High TLX1 expression | .03 | 0.72 (0.48-1.08) | .11 | 0.73 (0.49-1.09) | .12 | |
| NOTCH1 mutation | .02 | 0.72 (0.45-1.16) | .17 | NA | NA | |
| NOTCH1/FBXW7 mutation | .015 | NA | NA | 0.63 (0.39-1.02) | .06 | |
| For OS | ||||||
| In all patients | ||||||
| Age* | .03 | 1.03 (1.01-1.05) | .015 | 1.03 (1.01-1.05) | .03 | |
| WBC† | .09 | 1.16 (0.95-1.41) | .15 | 1.14 (0.94-1.39) | .19 | |
| GRAALL-2003 trial | .01 | 0.57 (0.33-0.99) | .05 | 0.55 (0.31-0.87) | .03 | |
| NOTCH1 mutation | .03 | 0.63 (0.39-1.01) | .06 | NA | NA | |
| NOTCH1/FBXW7 mutation | .004 | NA | NA | 0.54 (0.33-0.87) | .01 | |
| In the 127 patients tested for TLX1 expression | ||||||
| Age* | .08 | 1.03 (1.01-1.06) | .02 | 1.03 (1.01-1.05) | .04 | |
| WBC† | .08 | 1.17 (0.95-1.44) | .13 | 1.16 (0.94-1.42) | .16 | |
| GRAALL-2003 trial | .006 | 0.53 (0.29-0.96) | .35 | 0.50 (0.27-0.90) | .02 | |
| High TLX1 expression | .02 | 0.62 (0.39-0.99) | .05 | 0.64 (0.40-1.03) | .07 | |
| NOTCH1 mutation | .03 | 0.71 (0.43-1.18) | .19 | NA | NA | |
| NOTCH1/FBXW7 mutation | .005 | NA | NA | 0.61 (0.36-1.01) | .06 | |
| . | NOTCH1 . | NOTCH1/FBXW7 . | ||||
|---|---|---|---|---|---|---|
| Univariate P (95% CI) . | Multivariate HR (95% CI) . | P . | Multivariate HR (95% CI) . | P . | ||
| For EFS | ||||||
| In all patients | ||||||
| Age* | .22 | NA | NA | NA | NA | |
| WBC† | .08 | 1.11 (0.92-1.34) | .29 | 1.10 (0.91-1.32) | .33 | |
| GRAALL-2003 trial | < .001 | 0.44 (0.26-0.75) | .002 | 0.43 (0.25-0.72) | .001 | |
| NOTCH mutation | .03 | 0.68 (0.44-1.06) | .9 | NA | NA | |
| NOTCH1/FBXW7 mutation | .01 | NA | NA | 0.58 (0.37-0.92) | .02 | |
| In the 127 pateints tested for TLX1 expression | ||||||
| Age* | .27 | NA | NA | NA | NA | |
| WBC† | .05 | 1.12 (0.92-1.36) | .28 | 1.11 (0.92-1.35) | .28 | |
| GRAALL-2003 trial | < .001 | 0.42 (0.24-0.73) | .002 | 0.39 (0.22-0.69) | .001 | |
| High TLX1 expression | .03 | 0.72 (0.48-1.08) | .11 | 0.73 (0.49-1.09) | .12 | |
| NOTCH1 mutation | .02 | 0.72 (0.45-1.16) | .17 | NA | NA | |
| NOTCH1/FBXW7 mutation | .015 | NA | NA | 0.63 (0.39-1.02) | .06 | |
| For OS | ||||||
| In all patients | ||||||
| Age* | .03 | 1.03 (1.01-1.05) | .015 | 1.03 (1.01-1.05) | .03 | |
| WBC† | .09 | 1.16 (0.95-1.41) | .15 | 1.14 (0.94-1.39) | .19 | |
| GRAALL-2003 trial | .01 | 0.57 (0.33-0.99) | .05 | 0.55 (0.31-0.87) | .03 | |
| NOTCH1 mutation | .03 | 0.63 (0.39-1.01) | .06 | NA | NA | |
| NOTCH1/FBXW7 mutation | .004 | NA | NA | 0.54 (0.33-0.87) | .01 | |
| In the 127 patients tested for TLX1 expression | ||||||
| Age* | .08 | 1.03 (1.01-1.06) | .02 | 1.03 (1.01-1.05) | .04 | |
| WBC† | .08 | 1.17 (0.95-1.44) | .13 | 1.16 (0.94-1.42) | .16 | |
| GRAALL-2003 trial | .006 | 0.53 (0.29-0.96) | .35 | 0.50 (0.27-0.90) | .02 | |
| High TLX1 expression | .02 | 0.62 (0.39-0.99) | .05 | 0.64 (0.40-1.03) | .07 | |
| NOTCH1 mutation | .03 | 0.71 (0.43-1.18) | .19 | NA | NA | |
| NOTCH1/FBXW7 mutation | .005 | NA | NA | 0.61 (0.36-1.01) | .06 | |